Skip to main content

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

Recruiting · Phase 2 · NCT07029581

Conditions: Lewy Body Dementia Psychosis

At a glance

Research payments reported, 2025
$665,853
U.S. investigators named
12
Sites paid
12
Planned or actual enrollment
180

About the trial

Sponsor
ACADIA Pharmaceuticals Inc.
Tested
ACP-204 (drug), Placebo (drug)
Dates
Started 2025-08-06; completion 2028-03
Results posted
Not yet

Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.

From ClinicalTrials.gov, last updated 2026-11-04. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Acadia Pharmaceuticals Inc reported $665,853 in research payments for this study in 2025 (124 payments).

Products named: Acp-204

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Advanced Clinical Research Network Corp $186,164
  • Homestead Associates in Research Inc $135,010
  • Health Synergy Clinical Research LLC $123,725
  • Humanity Clinical Research Corp $74,111
  • K2 Summit Research LLC $22,750
  • K2 Medical Research Winter Garden LLC $22,750
  • Wcg Clinical Inc $19,995
  • University of Kansas Medical Center Research Institute Inc $19,750
  • Mediclear Medical $15,515
  • Movement Disorder Clinic of Oklahoma $12,161
  • Pns Clinical Research LLC $12,161
  • Abington Neurological Associates $12,161
  • $9,600

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.